Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
20,440 total articles
Candel Therapeutics, a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer treatment, announced inducement stock option grants totaling 70,000 shares to five new employees. These grants are made under the company's 2025 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The awards…
Minerva Neurosciences, a clinical-stage biotech focused on CNS disorders, announced that Jim O'Connor will become Chief Business Officer, replacing departing President Geoff Race who will remain as consultant. The leadership change occurs as Minerva prepares to advance its key drug candidate, roluperidone, through a planned Phase 3 trial targeting …
Financial Institutions, Inc., parent company of Five Star Bank and Courier Capital, announced it will release its Q1 2026 financial results after market close on April 23, 2026. The company will host an earnings conference call and webcast on April 24, 2026, to discuss the results.
Grocery Outlet Holding Corp., a U.S.-based extreme value retailer, announced the appointment of Frances Allen and Felicia Thornton to its Board of Directors to enhance expertise aligned with strategic priorities. Both bring extensive experience in grocery and retail sectors, brand strategy, marketing, finance, and operations. These strategic additi…
Ethos Technologies Inc., a life insurance technology company focused on democratizing access to life insurance, announced it will release its Q1 2026 financial results on May 6, 2026, after U.S. market close. The company also plans a conference call and live webcast for investors to discuss the results.
Relay Therapeutics announced it will present initial clinical and preclinical data on its lead drug candidate, zovegalisib, a mutant-selective PI3Kα inhibitor, in PIK3CA-driven vascular anomalies at the ISSVA World Congress 2026. Zovegalisib is also in advanced development for HR+/HER2- metastatic breast cancer and aims to address a large patient p…
Terns Pharmaceuticals, a clinical-stage oncology company, announced the granting of 23,316 restricted stock units to three new employees as inducement awards approved by the Compensation Committee, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years contingent on continued employment.
Rush Enterprises, the largest commercial vehicle dealership network in North America, announced it will host a conference call to discuss its first quarter 2026 earnings results on April 29, 2026, following the earnings release on April 28. The call will provide insights into the company's operational and financial performance across its extensive …
Oportun Financial Corporation announced that Kate Layton and Gaurav Rana will serve as interim co-CEOs following the departure of CEO Raul Vazquez. Both executives will retain their current roles while leading the company during the CEO search. Vazquez will continue as an advisor until July 2026 to facilitate a smooth transition. The board is activ…
Safe Bulkers, Inc., a marine drybulk transportation services provider, announced quarterly cash dividends of $0.50 per share on its 8.00% Series C and Series D Cumulative Redeemable Perpetual Preferred Shares, payable on April 30, 2026. Future dividends remain at the discretion of the Board of Directors, depending on company performance and financi…
Adagene Inc., a clinical-stage biotech company specializing in novel antibody-based cancer immunotherapies, announced the pricing of an underwritten public offering of 18.67 million ADSs at $3.75 each, raising gross proceeds of approximately $70 million. The offering attracted participation from both new and existing institutional investors and is …
ACM Research, a NASDAQ-listed semiconductor equipment supplier, introduced the ACM Planetary Family™, an organized product portfolio structured around eight core process steps in semiconductor manufacturing. This new portfolio aligns ACM's multi-product offerings to better meet evolving customer needs in front-end processing, advanced packaging, an…
Equillium, Inc., a clinical-stage biotechnology company focused on autoimmune and inflammatory disorders, announced inducement stock option grants of 32,000 shares to a new employee under its 2024 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing stock price on April 1, 2026, ves…
Microchip Technology has been certified by UL Solutions to the IEC 62443-4-1 Maturity Level 2 standard, confirming its secure development lifecycle for industrial automation and control system products. This certification demonstrates the company's capability in providing secure-by-design hardware and software, helping customers reduce supply chain…
PennantPark Investment Corporation announced it will pay a $0.08 per share monthly distribution for April 2026, split evenly between base and supplemental dividends, payable on May 1, 2026. The distribution is expected to be funded by taxable net investment income. The company primarily invests in U.S. middle-market private companies, offering a va…
Cartesian Therapeutics announced inducement stock option grants to two new employees, totaling 52,450 shares at an exercise price of $6.39 per share. The options vest over four years with a ten-year term, granted to attract talent under Nasdaq inducement rules. Cartesian is advancing its lead CAR-T therapy, Descartes-08, in clinical trials for auto…
Astera Labs, a semiconductor-based connectivity solutions provider for rack-scale AI infrastructure, announced it will release its Q1 2026 financial results after market close on May 5, 2026, followed by a conference call hosted by top executives to discuss the results and company outlook.
HMH Holding Inc., a provider of mission-critical drilling equipment and services for oil and gas operations, completed its initial public offering of 10.52 million Class A shares at $20.00 each, raising net proceeds of about $193.8 million. The shares commenced trading on The Nasdaq Global Select Market on April 1, 2026, under the symbol 'HMH'. The…
Annovis Bio announced it received a U.S. patent covering the use of its investigational drug buntanetap in preventing and treating neurological injuries caused by brain infections, including those linked to Alzheimer's disease. The patent extends through 2044 and covers both preventive and therapeutic applications against a range of infectious agen…
Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a reimbursement coverage agreement with Highmark for its CNSide CSF Tumor Cell Enumeration assay, increasing total covered lives from approximately 67 million to 75 million. This expands patient access and supports broader adoption of CNSide in the detection and monitoring of met…
Exicure, Inc., a clinical-stage biotech company listed on Nasdaq, has reached a settlement regarding consolidated stockholder derivative lawsuits alleging breach of fiduciary duty and misleading statements about its drug candidate, XCUR-FXN. The company will implement corporate governance reforms for four years and attorneys' fees of $675,000 will …
Context Therapeutics announced that the FDA has granted Fast Track Designation to its investigational drug CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, aimed at treating platinum-resistant ovarian cancer. The company is conducting a Phase 1 clinical trial with interim data expected in June 2026. This designation could expedite the de…
Praxis Precision Medicines announced restricted stock units totaling 3,558 shares granted to eighteen new non-executive employees as inducements to join the company under Nasdaq Listing Rule 5635(c)(4). These grants vest over four years, contingent on continued employment. Praxis is a CNS-focused biopharmaceutical company advancing therapies for ne…
MiNK Therapeutics disclosed that its investigational allogeneic iNKT cell therapy, agenT-797, will be featured at the ASGCT 2026 meeting. The therapy harnesses innate and adaptive immunity to target cancer, immune-mediated diseases, and severe pulmonary inflammation. The presentation underscores agenT-797's potential to modulate adaptive immune res…
FibroBiologics, a clinical-stage biotech company specializing in fibroblast-based therapeutics, closed a best efforts public offering raising approximately $3 million before fees. The offering included common stock and warrants exercisable upon stockholder approval, with potential additional proceeds of $3 million if warrants are exercised. Proceed…
